Holen Sie sich die Stockscreener-App
3.88
0.77%
-0.03
Handel nachbörslich:
3.89
0.01
+0.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.91
Offen:
$3.96
24-Stunden-Volumen:
4.73M
Relative Volume:
0.76
Marktkapitalisierung:
$919.83M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.8302
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
+4.58%
1M Leistung:
+2.37%
6M Leistung:
+215.45%
1J Leistung:
+78.80%
1-Tages-Spanne:
$3.78
$3.985
1-Wochen-Bereich:
$3.6301
$4.175
52-Wochen-Spanne:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.88 | 926.94M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Can Esperion Therapeutics Inc. stock sustain institutional interest2025 Market Sentiment & AI Driven Price Predictions - ulpravda.ru
Will Esperion Therapeutics Inc. (0ET) stock beat growth indexesQuarterly Performance Summary & Trade Opportunity Analysis - ulpravda.ru
Merger Talk: Is Esperion Therapeutics Inc. (0ET) stock considered safe haven2025 Winners & Losers & Reliable Momentum Entry Alerts - ulpravda.ru
Esperion Therapeutics gets Untitled Letter from FDA over Nexlizet ad - Medical Marketing and Media
How Esperion Therapeutics Inc. stock performs in rising dollar environmentQuarterly Profit Report & Technical Buy Zone Confirmations - ulpravda.ru
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Will Esperion Therapeutics Inc. (0ET) stock outperform value peersVolume Profile Analysis & Double Digit Returns - ulpravda.ru
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health - MedCity News
Esperion Therapeutics chief commercial officer sells $277 in stock - MSN
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
What analysts say about Esperion Therapeutics Inc stockMarket Volatility Update & Rapid Wealth Accumulation - earlytimes.in
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpWhat's Next? - MarketBeat
Is Esperion Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Rapid Wealth Building - earlytimes.in
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 4.8%Time to Sell? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
PFE6265887 Bond Coupon Analysis — Rate & Payments - TradingView — Track All Markets
Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week HighTime to Buy? - MarketBeat
Is Esperion Therapeutics Inc. stock attractive for long term wealth buildingPortfolio Update Summary & Real-Time Volume Triggers - Улправда
Will Esperion Therapeutics Inc. stock split attract more investorsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber
How Esperion Therapeutics Inc. (0ET) stock compares with top peersQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - DonanımHaber
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes - The Manila Times
Esperion's Bempedoic Acid Recognized by ACC as Effective LDL-C Lowering Therapy for Patients with PAD and Diabetes - Quiver Quantitative
Esperion’s Bempedoic Acid Receives Recommendation in 2025 - GlobeNewswire
Take Profit: Will Esperion Therapeutics Inc. stock maintain momentum in 2025 - DonanımHaber
Can Esperion Therapeutics Inc. stock hit record highs againJuly 2025 Macro Moves & AI Powered Market Entry Strategies - Улправда
Esperion Therapeutics Q3 2025 Earnings Preview - MSN
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan
Esperion Therapeutics (ESPR) CEO files Form 4 for 48,244-share tax sale - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay Sells 7,337 Shares - MarketBeat
Esperion Therapeutics Executives Sell Shares to Satisfy Tax Obligations - TradingView — Track All Markets
CFO Halladay Surrenders 7,337 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets
Esperion Therapeutics (ESPR) CFO reports 7,337-share sale for tax obligations - Stock Titan
Officer Looker Files To Sell 6,517 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets
PFE6265887 Bond Analysis — Key Metrics - TradingView — Track All Markets
Investors Purchase High Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month HighShould You Buy? - MarketBeat
Esperion’s Stock Surge: Opportunity Knocks? - StocksToTrade
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results - Yahoo Finance
Esperion announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Esperion Grants Stock Options and RSUs to New Chief Commercial Officer and Employees - Quiver Quantitative
Esperion Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Will Esperion Therapeutics Inc. (0ET) stock enhance shareholder valueEarnings Overview Summary & Smart Money Movement Alerts - Newser
Esperion stock hits fair value target with 77% gain since April 2024 - Investing.com Australia
Esperion Therapeutics, Inc.Common Stock (Nasdaq:ESPR) Stock Quote - Markets Financial Content
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Esperion Therapeutics Inc. (0ET) stock a top dividend aristocrat candidateTrend Reversal & Stepwise Trade Execution Plans - Newser
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Esperion Therapeutics Inc-Aktie (ESPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer |
Dec 17 '25 |
Sale |
3.67 |
7,337 |
26,905 |
467,525 |
| Looker Benjamin | General Counsel |
Dec 17 '25 |
Sale |
3.67 |
6,517 |
23,898 |
385,905 |
0.37%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):